North America Prefilled Syringes Market to Reach USD 17.46 Billion by 2035, Driven by Biologics and Home Self-Administration
核心洞察
The North America prefilled syringes market is valued at USD 6.26 billion in 2025 and is projected to reach USD 17.46 billion by 2035, expanding at a CAGR of 10.80% from 2026 to 2035.
Growth is driven by rising chronic disease prevalence, an aging population, increasing use of complex biologic drugs, and strong preference for self-administered injectable treatments at home.
Conventional prefilled syringes held a 62.00% share in 2025, while glass dominated the material segment at 78.00%, and diabetes (搜索) led applications at 28.00%.
The North America prefilled syringes market is calculated at USD 6.26 billion in 2025 and is predicted to gain around USD 17.46 billion by 2035, expanding at a CAGR of 10.80% from 2026 to 2035. The increasing rates of chronic diseases such as diabetes (搜索), an aging population, a rise in the use of complex biologic drugs, and a strong preference for self-administered injectable treatments at home mainly drive the market.
The market is essential for global advancements in safe drug delivery. It is fueled by the growing prevalence of chronic illnesses, a trend towards self-administration at home, and a significant dependence on complex biologic drugs that need accurate and sterile dosing. High incidences of diabetes (搜索), rheumatoid arthritis (搜索), and heart diseases create a demand for dependable, long-term, and precise drug delivery systems.
Complex biologic drugs and biosimilars require specialized, sterile packaging, such as prefilled syringes, to ensure stability and accurate dosing. Patients and caregivers favor easy-to-use, premeasured injectors that minimize the chances of dosing mistakes and needle-stick injuries outside medical facilities. Strict regulatory standards set by health authorities emphasize the need for safety-engineered devices to safeguard both healthcare workers and patients.
Market Segmentation by Type
Conventional prefilled syringes dominate the North America prefilled syringes market, holding a share of 62.00% in 2025, due to their cost-effectiveness, high reliability, and strong trust among users in hospitals and clinics. These standard devices minimize preparation time, reduce waste from vial transfers, and guarantee accurate dosing for well-established therapies.
The safety prefilled syringes segment, with a share of 38.00% in 2025, is essential in North America because the built-in needle-shielding features help prevent accidental needlestick injuries for healthcare professionals. Strict regional health regulations, a high demand for safe self-administration at home, and a strong emphasis on reducing infection risks drive this important market segment.
Material and Product Analysis
The glass segment, with a share of 78.00% in 2025, leads the North American prefilled syringes market since glass is chemically inert, avoiding harmful reactions with sensitive medications. It acts as a strong barrier against air and moisture, complies with strict regulations for biologics and vaccines, and adheres to trusted manufacturing standards. The plastic segment, with a share of 22.00% in 2025, plays a crucial role due to its high break resistance, lightweight nature, and compatibility with advanced polymers (like Cyclic Olefin Polymers) for self-administered biologics and home healthcare.
The Complete Syringe Set segment, with a share of 74.00% in 2025, dominates the market, as it offers ready-to-use, pre-assembled systems that reduce preparation time, eliminate medication transfer errors, and facilitate the quick transition to at-home chronic disease management and self-administration. The components and accessories segment, with a share of 26.00% in 2025, including plunger stoppers, needle shields, tip caps, and safety devices, ensures drug stability, prevents contamination, and complies with strict FDA safety requirements for advanced biologics and at-home chronic care.
Application and End-User Insights
The diabetes (搜索) segment, with a share of 28.00% in 2025, accounts for the largest revenue share in the North America prefilled syringes market, as millions of patients need daily, accurate insulin self-injections. Prefilled syringes and pen injectors help minimize dosage mistakes, lower contamination risks, and provide the convenience and safety essential for managing chronic diseases. The rheumatoid arthritis (搜索) segment, with a share of 17.00% in 2025, boosts the need for home self-administration of biologic medications, reduces expensive clinical visits, and benefits from a strong regional healthcare system and insurance support.
The pharmaceutical and biotechnology companies segment, with a share of 68.00% in 2025, dominates the market by developing, marketing, and packaging high-value biologic drugs, vaccines, and complex injectables that need precise dosing, long shelf life, and built-in safety features. The Contract Research and Manufacturing Organizations (CRAMO/CMO) segment, with a share of 21.00% in 2025, offers specialized aseptic filling capabilities, manages complex biologic drug formulations, and helps pharmaceutical companies save on capital costs while meeting strict FDA regulations.
Competitive Landscape
The North America prefilled syringes market is rapidly expanding due to the increase in chronic diseases, home healthcare, and biologic medications. Key global companies such as BD, Gerresheimer, SCHOTT Pharma, and West Pharmaceutical Services lead the market with their specialized glass and polymer syringe products.
Becton, Dickinson and Company (BD) (搜索) is recognized as a top player, offering popular products like BD Hypak, BD Sterifill Advance, and BD SafetyGlide, along with all-in-one flush syringes. Gerresheimer AG (搜索) provides a wide variety of prefillable glass and plastic syringe systems, ensuring user safety with additional features and accessories for biotech and pharmaceutical partners. SCHOTT Pharma is increasing domestic manufacturing in North America with specialized polymer and glass prefillable syringes designed for the safe storage of high-viscosity biologic drugs. West Pharmaceutical Services, Inc. (搜索) offers fully integrated containment systems that combine custom syringe barrels with high-performance stoppers, plungers, and needle safety accessories. Terumo Corporation delivers innovative prefillable syringe solutions that include silicone oil-free stopper technologies to prevent protein clumping in delicate biologic medicines. Stevanato Group (搜索) produces high-quality, ready-to-fill sterilized glass syringes and specialized coating technologies that are ideal for precision biologics and insulin storage.